<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Rabeprazole</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01129</strong>&#160; (APRD01212)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug &#8211; in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01129/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01129/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01129.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01129.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01129.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01129.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01129.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01129">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Clofezone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Rabeprazole Sodium</strong>
          <div class="cas">117976-90-6</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000552/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000552/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: KRCQSTCYZUOBHN-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 381.112306886</li>
              <li>Average Mass: 381.424</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000552">DBSALT000552</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>AcipHex</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Pariet</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/enzyme-inhibitors">Enzyme Inhibitors</a></li>
<li><a href="/mesh/anti-ulcer-agents">Anti-Ulcer Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>117976-89-3</td></tr><tr><th>Weight</th><td>Average: 359.443<br>Monoisotopic: 359.130362243</td></tr><tr><th>Chemical Formula</th><td>C<sub>18</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub>S</td></tr><tr><th>InChI Key</th><td>YREYEVIYCVEVJK-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methane}sulfinyl)-1H-1,3-benzodiazole</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzimidazoles</td></tr><tr><th>Subclass</th><td>Sulfinylbenzimidazoles</td></tr><tr><th>Direct parent</th><td>Sulfinylbenzimidazoles</td></tr><tr><th>Alternative parents</th><td>Alkyl Aryl Ethers; Pyridines and Derivatives; Benzene and Substituted Derivatives; Imidazoles; Sulfoxides; Polyamines</td></tr><tr><th>Substituents</th><td>alkyl aryl ether; pyridine; benzene; azole; imidazole; sulfoxide; polyamine; ether; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.</td></tr><tr><th>Pharmacodynamics</th><td>Rabeprazole prevents the production of acid in the stomach. It reduces symptoms and prevents injury to the esophagus or stomach in patients with gastroesophageal reflux disease (GERD) or ulcers. Rabeprazole is also useful in conditions that produce too much stomach acid such as Zollinger-Ellison syndrome. Rabeprazole may also be used with antibiotics to get rid of bacteria that are associated with some ulcers. Rabeprazole is a selective and irreversible proton pump inhibitor, suppresses gastric acid secretion by specific inhibition of the H<sup>+</sup>, K<sup>+</sup> -ATPase, which is found at the secretory surface of parietal cells. In doing so, it inhibits the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen.</td></tr><tr><th>Mechanism of action</th><td>Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H<sup>+</sup>/K<sup>+</sup>ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds.</td></tr><tr><th>Absorption</th><td>Absolute bioavailability is approximately 52%.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>96.3% (bound to human plasma proteins)</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Rabeprazole</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01169">Active Metabolite of Rabeprazole</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1304">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Following a single 20 mg oral dose of 14C-labeled rabeprazole, approximately 90% of the drug was eliminated in the urine, primarily as thioether carboxylic acid; its glucuronide, and mercapturic acid metabolites.</td></tr><tr><th>Half life</th><td>1-2 hours (in plasma)</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9967</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.6469</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6664</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6179</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.5835</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9387</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.6194</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8265</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8623</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7174</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.6677</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7734</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7875</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.6661</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6647</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.7243</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5726
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8751
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.939
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.4215 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Strong inhibitor 
        </td>
        <td>
            0.5726
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8733
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Eisai inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Eisai Corporation</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li>DRX Pharmaceuticals</li>
<li><a href="http://www.eisai.com">Eisai Inc.</a></li>
<li><a href="http://www.janssen-ortho.com">Janssen-Ortho Inc.</a></li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet, coated</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Aciphex 20 mg Enteric Coated Tabs</td><td>7.48USD</td><td>tab</td></tr><tr><td>Aciphex ec 20 mg tablet</td><td>6.08USD</td><td>tablet</td></tr><tr><td>Aciphex 20 mg tablet ec</td><td>5.9USD</td><td>tablet</td></tr><tr><td>Pariet 20 mg Enteric-Coated Tablet</td><td>1.46USD</td><td>tablet</td></tr><tr><td>Apo-Rabeprazole 20 mg Enteric-Coated Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Novo-Rabeprazole 20 mg Enteric-Coated Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Pms-Rabeprazole Ec 20 mg Enteric-Coated Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Ran-Rabeprazole 20 mg Enteric-Coated Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Sandoz Rabeprazole 20 mg Enteric-Coated Tablet</td><td>0.82USD</td><td>tablet</td></tr><tr><td>Pariet 10 mg Enteric-Coated Tablet</td><td>0.73USD</td><td>tablet</td></tr><tr><td>Apo-Rabeprazole 10 mg Enteric-Coated Tablet</td><td>0.41USD</td><td>tablet</td></tr><tr><td>Novo-Rabeprazole 10 mg Enteric-Coated Tablet</td><td>0.41USD</td><td>tablet</td></tr><tr><td>Pms-Rabeprazole Ec 10 mg Enteric-Coated Tablet</td><td>0.41USD</td><td>tablet</td></tr><tr><td>Ran-Rabeprazole 10 mg Enteric-Coated Tablet</td><td>0.41USD</td><td>tablet</td></tr><tr><td>Sandoz Rabeprazole 10 mg Enteric-Coated Tablet</td><td>0.41USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>5045552</td><td>1993-05-08</td><td>2013-05-08</td></tr><tr><td>Canada</td><td>2104531</td><td>1999-01-05</td><td>2013-08-20</td></tr><tr><td>Canada</td><td>1336958</td><td>1995-09-12</td><td>2012-09-12</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>logP</td><td>0.6</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>3.36e-01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.04</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.09</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-3</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>9.35</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>4.24</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>77.1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>8</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>98.07</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>39.64</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Sundaram Venkatraman, &#8220;Crystalline form Z of rabeprazole sodium and process for preparation thereof.&#8221; U.S. Patent US20040180935, issued September 16, 2004.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=20040180935&amp;tbm=pts" target="_blank">US20040180935 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C07864" target="_blank">C07864 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5029" target="_blank">5029 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46506366" target="_blank">46506366 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.4853.html" target="_blank">4853 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=8768" target="_blank">8768 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1219" target="_blank">CHEMBL1219 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000727" target="_blank">DAP000727 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA451216" target="_blank">PA451216 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2243797" target="_blank">2243797 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic3/aciphex.htm" target="_blank">http://www.rxlist.com/cgi/generic3/aciphex.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/rabeprazole.html" target="_blank">http://www.drugs.com/cdi/rabeprazole.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PDRhealth</td><td><a class="wishart-link-out" href="http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/aci1534.shtml" target="_blank">http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/aci1534.shtml <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Rabeprazole" target="_blank">Rabeprazole <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>A02BC04<ul class="atc-drug-tree"><li><a href="/atc/A#A">A &#8212; ALIMENTARY TRACT AND METABOLISM</a></li><li><a href="/atc/A02#A02">A02 &#8212; DRUGS FOR ACID RELATED DISORDERS</a></li><li><a href="/atc/A02B#A02B">A02B &#8212; DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)</a></li><li><a href="/atc/A02BC#A02BC">A02BC &#8212; Proton pump inhibitors</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>56:28.36</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB01129.pdf?1265922803">show</a>(135 KB)</td></tr><tr><th>MSDS</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Rabeprazole may decrease the serum levels and therapeutic effects of atazanavir.</td></tr><tr><td><a href="/drugs/DB01066">Cefditoren</a></td><td>Proton pump inhibitors such as rabeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.</td></tr><tr><td><a href="/drugs/DB00758">Clopidogrel</a></td><td>Rabeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent rabeprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with rabeprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel.</td></tr><tr><td><a href="/drugs/DB01254">Dasatinib</a></td><td>Rabeprazole may decrease the serum level of dasatinib.</td></tr><tr><td><a href="/drugs/DB00390">Digoxin</a></td><td>Rabeprazole increases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB00467">Enoxacin</a></td><td>Rabeprazole may decrease the absorption of enoxacin.</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Omeprazole decreases the absorption of indinavir</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>The proton pump inhibitor, rabeprazole, may decrease the absorption of itraconazole.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>The proton pump inhibitor, rabeprazole, may decrease the absorption of ketoconazole.</td></tr><tr><td><a href="/drugs/DB08864">Rilpivirine</a></td><td>Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy. </td></tr><tr><td><a href="/drugs/DB00755">Tretinoin</a></td><td>The moderate CYP2C8 inhibitor, Rabaprazole, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rabaprazole is initiated, discontinued to dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals.</li>
<li>Take without regard to meals. Food may slow absorption rate but extent of absorption is not affected.</li></ul></td></tr></tbody></table>